Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

1(16.7%)

Phase 4

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 3(3)

Phase 2(1)

Phase 4(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04906395Phase 3Active Not Recruiting

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Role: lead

NCT05645536Phase 3Enrolling By Invitation

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Role: lead

NCT06385509Phase 4Active Not Recruiting

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

Role: lead

NCT04249154Phase 2Recruiting

Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Role: collaborator

NCT02452931Phase 3Completed

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Role: lead

NCT03122353Phase 1Completed

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

Role: lead

All 6 trials loaded